Robert Orlowski
M.D. Anderson Cancer Center · UT MD Anderson Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Robert Orlowski as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:27 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT06105554 · Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple MyelomaM.D. Anderson Cancer Center · recruiting · Multiple Myeloma · principal investigator
- Ph1NCT05055063 · A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple MyelomaM.D. Anderson Cancer Center · recruiting · Myeloma · principal investigator
- Ph1NCT01807286 · Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL AmyloidosisM.D. Anderson Cancer Center · terminated · Myeloma · principal investigator
- Ph2NCT01793051 · Intervention for Symptom Burden During Maintenance Therapy for Multiple MyelomaM.D. Anderson Cancer Center · completed · Myeloma · principal investigator
- Ph2NCT01447914 · Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple MyelomaNational Cancer Institute (NCI) · completed · Refractory Multiple Myeloma · principal investigator
- Ph1NCT01372540 · Filanesib and Carfilzomib in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell LeukemiaM.D. Anderson Cancer Center · completed · Plasma Cell Leukemia, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma · principal investigator
- Ph1NCT01301807 · Panobinostat and Carfilzomib in Treating Participants With Relapsed or Refractory Multiple MyelomaM.D. Anderson Cancer Center · completed · Non-Secretory Plasma Cell Myeloma, Plasmacytosis, Recurrent Plasma Cell Myeloma · principal investigator
- Ph2NCT01269203 · Efficacy of NF-kB Inhibition for Reducing Symptoms During Maintenance Therapy in Multiple Myeloma PatientsM.D. Anderson Cancer Center · withdrawn · Multiple Myeloma · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 09:27 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Role of Heat Shock Protein 70 as a Mediator and Therapeutic Target in T-cell LymphomasR01CA266612 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2022 to 2026 · $483,912 awarded in 2026Same name and institution; not confirmed by an ID
- 12 Hematologic MalignanciesP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2019 to 2025 · $24,690 awarded in 2025Grant number is on one of their registry trials
- Proteasome Assembly Chaperones in Sensitivity and Resistance to Proteasome InhibitorsR01CA194264 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2016 to 2020 · $359,851 awarded in 2020Same name and institution; not confirmed by an ID
- Role of TJP1 in Sensitivity and Resistance to Proteasome Inhibitors in MyelomaR01CA184464 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2015 to 2019 · $345,591 awarded in 2019Same name and institution; not confirmed by an ID
- M. D. Anderson Cancer Center SPORE in Multiple MyelomaP50CA142509 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2010 to 2014 · $2,161,999 awarded in 2014Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- TARGETING NF-KB ACTIVATION IN REGULATION OF SYMPTOMS IN PATIENTS WITH MULTIPLEP01CA124787 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Bharat B Aggarwal · fiscal years 2008 to 2012Named on NCT01793051
- Phase I Studies of Targeted Anti-Cancer TherapiesU01CA062461 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI James C Yao · fiscal years 1994 to 2013Named on NCT01447914
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 09:27 UTC. The ranking covers the 200 most relevant of 126 PubMed records, and a shared surname and initials can bring in a namesake. All 126 on PubMed
- A phase 2 study of bortezomib in relapsed, refractory myeloma.N Engl J Med · 20032,213 citationsRCR 42.2
- 1,411 citationsRCR 40.2
- Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.N Engl J Med · 20161,208 citationsRCR 41.0
- Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.N Engl J Med · 20151,116 citationsRCR 34.1
- Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.N Engl J Med · 2019853 citationsRCR 33.9
- Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer.N Engl J Med · 2022818 citationsRCR 55.4
- 773 citationsRCR 27.7
- 756 citationsRCR 25.0
- 715 citationsRCR 23.2
- 625 citationsRCR 29.5